Healthcare products
Child Health
Deficiency States and Supplementation
Dermatological Health
Pain treatment
Gastrointestinal Health
Genitourinary Health
Cardiorespiratory Health
Corticotherapy
Oral-Pharyngeal Health
Fluid Therapy
CNS Treatment
Laboratorios ERN’s Presence at the Meeting with the President of the Spanish Government
Laboratorios ERN’s Presence at the Meeting with the President of the Spanish Government
David Solanes López, General Director of Laboratorios ERN, met on February 12, 2025, with the President of the Government of Spain, Pedro Sánchez, along with other executives from the national and multinational pharmaceutical industry, Farmaindustria, EFPIA, and the Minister of Health, Mónica García, the Minister of Industry, Jordi Hereu, and other members of the Government.
Following the first meeting held in December 2022, which marked the launch of the work plan and the publication of the Pharmaceutical Industry Strategy, this second meeting highlighted the importance of pharmaceutical companies’ plans, emphasizing the sector’s commitment to Spain and announcing that between 2023 and 2025, pharmaceutical investment will exceed €8 billion. This investment reaffirms the strategic role of the industry in innovation, sustainability, and the creation of high-quality jobs.
Additionally, David Solanes intervened, requesting that the Administration consider the sustainability of national pharmaceutical SMEs when introducing legislative changes. As an example, he mentioned the impact that the Urban Wastewater Treatment Directive could have on the future of pharmaceutical SMEs and their employees, as it would be entirely unfeasible if implemented under the current terms.
In this context, it was emphasized that the pharmaceutical industry is a key asset and a fundamental sector for strengthening public-private collaboration and consolidating Spain as a leader in biomedical research and production. Furthermore, the implementation of legislative reforms, such as the Royal Decree on Health Technology Assessment and the Royal Decree on Pricing and Financing, will help facilitate access to new medicines and promote a stable and predictable regulatory environment.
Looking ahead, the pharmaceutical industry’s commitment to innovation and sustainability will continue to be essential in ensuring access to effective treatments and improving the population’s quality of life. At Laboratorios ERN, we will continue to invest in the development of innovative solutions, aligning with national and European strategies to strengthen the pharmaceutical ecosystem. The combination of investment, collaboration, and scientific advancements will enable Spain to further consolidate its position as a benchmark in biomedical research, fostering sustainable growth that benefits society as a whole.
noticias relacionadas
Laboratorios ERN signs a collaboration agreement with Lupin Limited and launches a new medicine in Spain for the treatment of asthma and COPD
With more than 80 years of history, the laboratory founded in Barcelona continues to advance its sustainable growth strategy through alliances with leading international partners. Laboratorios ERN is taking a decisive step in strengthening its respiratory portfolio with the launch in Spain of Luforbec® (beclometasone / formoterol), 100/6, a fixed-dose combination in a pressurised metered-dose […]
Laboratorios ERN and Ercros, beneficiaries of CDTI funding for the development of the ANTISALINA project
Laboratorios ERN and Ercros are beneficiaries of public funding awarded under the National Cooperative R&D Programme of the Centre for the Development of Technology and Innovation (CDTI). Thanks to this funding, both companies are jointly advancing the ANTISALINA project, aimed at developing new innovative solutions in the field of research and experimental development. At Laboratorios […]
Launch of Intravenous Fosfomycin Commercialization in the United States
The commercialization of intravenous fosfomycin has begun in the United States. This hospital-use antibiotic is a key treatment for complicated urinary tract infections and is being introduced through a strategic agreement between LABORATORIOS ERN and the pharmaceutical company Meitheal Pharmaceuticals, a specialist in the commercialization of generic and biologic injectable products. Intravenous fosfomycin was approved […]
Laboratorios ERN joins the Fundación Empresa y Clima (FEC) as a Silver member
We are proud to announce that Laboratorios ERN has officially joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing our commitment to climate action and global sustainability. This alliance allows us to become part of a business community committed to the transition toward a low-carbon economy, alongside other companies that share the […]
ERN Laboratories supports research into pediatric rare diseases at Sant Joan de Déu Hospital in Barcelona.
During 2026, ERN Laboratories will allocate €1 for each unit sold of Astenolit Infantil, a nutritional supplement designed to support children’s energy levels and immune defenses, to benefit pediatric rare disease research at Sant Joan de Déu. This initiative is part of ERN Laboratories’ longstanding commitment to pediatrics and child health, supporting projects that contribute […]